Supplementary Data from Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti–PD-1 Immunotherapy

Wenjie You,Lijun Li,Deqiao Sun,Xueqing Liu,Zongjun Xia,Shan Xue,Bi Chen,Hui Qin,Jing Ai,Handong Jiang

DOI: https://doi.org/10.1158/2326-6066.22539082

2023-01-01

Abstract:Supplementary Table 1, Supplementary Figures 1-7

What problem does this paper attempt to address?

Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti–PD-1 Immunotherapy

Wenjie You,Lijun Li,Deqiao Sun,Xueqing Liu,Zongjun Xia,Shan Xue,Bi Chen,Hui Qin,Jing Ai,Handong Jiang

DOI: https://doi.org/10.1158/2326-6066.cir-17-0672

IF: 10.1

2019-01-01

Cancer Immunology Research

Abstract:The farnesoid X receptor (FXR) regulates inflammation and immune responses in a subset of immune-mediated diseases. We previously reported that FXR expression promotes tumor cell proliferation in non-small cell lung cancer (NSCLC). Here we study the relevance of FXR to the immune microenvironment of NSCLC. We found an inverse correlation between FXR and PD-L1 expression in a cohort of 408 NSCLC specimens; from this, we identified a subgroup of (FXRPD)-P-high-L1(low) patients. We showed that FXR downregulates PD-L1 via transrepression and other mechanisms in NSCLC. Cocultured with (FXRPD)-P-high-L1(low) NSCLC cell lines, effector function and proliferation of CD8(+) T cell in vitro are repressed. We also detected downregulation of PD-L1 in FXR-overexpressing Lewis lung carcinoma (LLC) mouse syngeneic models, indicating an (FXRPD)-P-high-L1(low) subtype in which FXR suppresses tumor-infiltrating immune cells. Anti-PD-1 therapy was effective against (FXRPD)-P-high-L1(low) mouse LLC tumors. Altogether, our findings demonstrate an immunosuppressive role for FXR in the (FXRPD)-P-high-L1(low) NSCLC subtype and provide translational insights into therapeutic response in PD-L1(low) NSCLC patients treated with anti-PD-1. We recommend (FXRPD)-P-high-L1(low) as a biomarker to predict responsiveness to anti-PD-1 immunotherapy.
Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[<sup>18</sup>F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect

Xuejun Wen,Changrong Shi,Xinying Zeng,Liang Zhao,Lanlin Yao,Zhida Liu,Lixia Feng,Deliang Zhang,Jinxiong Huang,Yesen Li,Qin Lin,Haojun Chen,Rongqiang Zhuang,Xiaoyuan Chen,Xianzhong Zhang,Zhide Guo

DOI: https://doi.org/10.1158/1078-0432.22486374

2023-01-01

Abstract:Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[<sup>18</sup>F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Tao Jiang,Qiqi Jin,Jiahao Wang,Fengying Wu,Jian Chen,Gongyan Chen,Yunchao Huang,Jianhua Chen,Ying Cheng,QiMing Wang,Yueyin Pan,Jianying Zhou,Jianhua Shi,Xingxiang Xu,LiZhu Lin,Wei Zhang,Yiping Zhang,Yunpeng Liu,Yong Fang,Jifeng Feng,Zhehai Wang,Sheng Hu,Jian Fang,Yongqian Shu,Jiuwei Cui,Yi Hu,Wenxiu Yao,Xingya Li,Xiaoyan Lin,Rui Wang,Yongsheng Wang,Wei Shi,Gaohua Feng,Jun Ni,Beibei Mao,Dandan Ren,Huaibo Sun,Henghui Zhang,Luonan Chen,Caicun Zhou,Shengxiang Ren

DOI: https://doi.org/10.1158/1078-0432.23791953.v1

2023-01-01

Abstract:Supplementary Materials
Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Jialei Weng,Zheng Wang,Zhiqiu Hu,Wenxin Xu,Jia-Lei Sun,Fu Wang,Qiang Zhou,Shaoqing Liu,Min Xu,Minghao Xu,Dongmei Gao,Ying-Hao Shen,Yong Yi,Yi Shi,Qiongzhu Dong,Chenhao Zhou,Ning Ren

DOI: https://doi.org/10.1158/0008-5472.25964573.v1

2024-01-01

Abstract:The Supplementary Data consist of: Supplementary Tables S1-7
High Farnesoid X Receptor Expression Predicts Favorable Clinical Outcomes in PD‑L1low/negative Non‑small Cell Lung Cancer Patients Receiving Anti‑pd‑1‑based Chemo‑immunotherapy.

Lina Wang,Xiaolong Xu,Bin Shang,Jian Sun,Bin Liang,Xingguang Wang,Wenjie You,Shujuan Jiang

DOI: https://doi.org/10.3892/ijo.2022.5330

2022-01-01

International Journal of Oncology

Abstract:Anti‑programmed death‑1 (PD‑1)/programmed death‑ligand 1 (PD‑L1)‑directed immunotherapy has revolutionized the treatment of advanced non‑small cell lung cancer (NSCLC). However, predictive biomarkers are still lacking, particularly in identifying PD‑L1low/negative patients who will benefit from immunotherapy. It was previously reported that farnesoid X receptor (FXR) downregulated PD‑L1 expression in NSCLC, and that FXRhighPD‑L1low mouse Lewis lung carcinoma tumors showed an increased susceptibility to PD‑1 blockade compared with mock tumors. At present, whether the FXRhighPD‑L1low phenotype predicts clinical response to immunotherapy in patients with NSCLC remains unclear. Herein, a retrospective study was conducted to examine the expression levels of FXR, PD‑L1 and CD8+ T cells by immunohistochemistry in a cohort of 149 patients with NSCLC receiving anti‑PD‑1‑based chemo‑immunotherapy. The results revealed that high FXR and PD‑L1 expression levels were associated with higher objective response rates (ORR) in all patients. High PD‑L1 expression also indicated superior progression‑free survival (PFS). Interestingly, an inverse correlation was identified between FXR and PD‑L1 expression in specimens with NSCLC. Subgroup analysis revealed that high FXR expression was associated with a higher ORR, as well as longer PFS and overall survival (OS) in PD‑L1low patients. Cox multivariate analysis revealed that high FXR expression was an independent predictor for PFS and OS in PD‑L1low patients. Tumor microenvironment evaluation revealed a statistically significant decrease of infiltrating CD8+ T cells in FXRhigh specimens with NSCLC. Overall, the present study proposed an FXRhighPD‑L1low signature as a candidate predictor of response to anti‑PD‑1‑based chemo‑immunotherapy in PD‑L1low/negative patients with NSCLC, providing evidence that could be used to broaden the patients benefitting from immunotherapy.
Supplementary Data from Genomic Characteristics and Single-Cell Profiles after Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma

Pei Dong,Xinyue Zhang,Yulu Peng,Yijun Zhang,Ruiqi Liu,Yilin Li,Qiwen Pan,Wensu Wei,Shengjie Guo,Zhiling Zhang,Hui Han,Fangjian Zhou,Yang Liu,Liru He

DOI: https://doi.org/10.1158/1078-0432.22488746.v1

2023-01-01

Abstract:Supplementary Data from Genomic Characteristics and Single-Cell Profiles After Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma
Supplementary Data from XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti–PD-1 Efficacy

Kun Chen,Zhiyuan Wu,Hong Zhao,Yanmei Wang,Yutong Ge,Dongmei Wang,Zhengjiang Li,Changming An,Yuying Liu,Feifei Wang,Xinyu Bi,Hongying Wang,Jianqiang Cai,Chunhong Ma,Chunfeng Qu

DOI: https://doi.org/10.1158/2326-6066.22543440

2023-01-01

Abstract:Supplementary Tables 1-2 and Supplementary Figures 1-8
Supplementary Data from LRP6 Ectodomain Prevents SDF-1/CXCR4-Induced Breast Cancer Metastasis to Lung

Jiankang Zhang,Jingxiao Chen,Wang Da,Hongyuan Yan,Peng Liu,Evan Ma,Limei Li,Lirong Zheng,Daxin Chen,Zuoren Yu,Chao Liang,Jun Peng,Dan‐ni Ren,Weidong Zhu

DOI: https://doi.org/10.1158/1078-0432.22471844.v1

2023-01-01

Abstract:Supplementary Figures, Figure legends and Tables
Supplementary Table 4 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity

Xiaomin Zhang,Limin Cheng,Chengqi Gao,Jing Chen,Shuangye Liao,Yongqiang Zheng,Liping Xu,Jingjing He,Danyang Wang,Ziqian Fang,Jianeng Zhang,Min Yan,Yi Luan,Siyu Chen,Likun Chen,Xiaojun Xia,Chunhao Deng,Guokai Chen,Wende Li,Zexian Liu,Penghui Zhou

DOI: https://doi.org/10.1158/0008-5472.22433570

2023-01-01

Abstract:Clinical characteristics for the NSCLC cohort analyzed sex difference of survival in patients treated with anti-PD-1 antibody
Supplementary Data from PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses Against Tumor

Liangrong Shi,Lujun Chen,Changping Wu,Yibei Zhu,Bin Xu,Xiao Zheng,Mingfen Sun,Wen,Xichao Dai,Min Yang,Quansheng Lv,Binfeng Lu,Jingting Jiang

DOI: https://doi.org/10.1158/1078-0432.22457843

2023-01-01

Abstract:Supplemental figure 1. Patient cohort and study design. Supplemental Figure 2. Immunochemical staining of PD-L1 antibody (1:500, clone: SP142) on the paraffin-embedded human melanoma and placenta tissues. Supplemental Figure 3. RFA of colorectal liver metastases increased PD-L1 expression on infiltrating immune cells. Supplemental Figure 4. Correlation between PD-L1 expression on tumor cells and the intensity of CD8+, CD4+ T cell infiltration in endoscopic biopsy (A, B) and resected tumor specimen (C, D) (all of 78 patients were included). Supplemental Figure 5. RFA increased CD45+ immune cells and T cells infiltrating into contralateral tumor. Supplemental Figure 6. RFA increased T cells infiltration and PD-1/PD-L1 expression in a disdant tumor in B16 tumor-bearing mice. Supplemental Figure 7. RFA did not upregulate PD-1/PD-L1 expression in splenic lymphocytes. Supplemental Figure 8. RFA increased Tim-3, CD160, CD244 and eomes expression in a disdant tumor in CT26 tumor-bearing mice. Supplemental Figure 9. RFA and the anti-PD-1 therapy increased CD8+TIL cell infiltration in distant tumor. Supplemental Figure 10. RFA and the anti-PD-1 therapy upregulated Tim-3 expression on T cells in a distant tumor. Supplemental Table 1 Primer sequences used for the detection of gene expression by RT-QPCR Supplemental Table 2 Patient characteristic Supplemental table 3. Multivariate analysis of factors related to increased PD-L1 expression in resected tumor specimen.
Supplementary Table 5 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity

Xiaomin Zhang,Limin Cheng,Chengqi Gao,Jing Chen,Shuangye Liao,Yongqiang Zheng,Liping Xu,Jingjing He,Danyang Wang,Ziqian Fang,Jianeng Zhang,Min Yan,Yi Luan,Siyu Chen,Likun Chen,Xiaojun Xia,Chunhao Deng,Guokai Chen,Wende Li,Zexian Liu,Penghui Zhou

DOI: https://doi.org/10.1158/0008-5472.22433567.v1

2023-01-01

Abstract:Clinical characteristics for melanoma cohort analyzed sex difference of survival in patients treated with anti-PD-1 antibody
Supplementary Data from Regorafenib Promotes Antitumor Immunity Via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Rui-Yan Wu,Peng-Fei Kong,Liang-Ping Xia,Yun Huang,Zhi-Ling Li,Yun-Yun Tang,Yu-Hong Chen,Xuan Li,Ravichandran Senthilkumar,Hai-Liang Zhang,Ting Sun,Xue-Lian Xu,Yan Yu,Jia Mai,Xiao-Dan Peng,Dong Yang,Li-Huan Zhou,Gong-Kan Feng,Rong Deng,Xiao-Feng Zhu

DOI: https://doi.org/10.1158/1078-0432.22471275.v1

2023-01-01

Abstract:Supplementary Figures + Supplementary Datas
Supplementary Figure from IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment

Bo Hu,Mincheng Yu,Xiaolu Ma,Jialei Sun,Chenglong Liu,Chunyan Wang,Suiyi Wu,Peiyao Fu,Zhen Yang,Yungang He,Yuanyuan Zhu,Cheng Huang,Xinrong Yang,Yinghong Shi,Shuangjian Qiu,Huichuan Sun,Andrew X. Zhu,Jian Zhou,Yang Xu,Di Zhu,Jia Fan

DOI: https://doi.org/10.1158/2159-8290.cd-21-1022

IF: 28.2

2022-01-01

Cancer Discovery

Abstract:Supplementary Figure from IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment
Supplementary Data from Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC

Pedro Rocha,Jiexin Zhang,Raquel Laza-Briviesca,Alberto Cruz-Bermúdez,Neus Bota-Rabassedas,Beatriz Sanchez-Espiridon,Kazuhito Funai,Carmen Behrens,Wei Lü,Ximing Tang,Apar Pataer,Edwin R. Parra,Cara Haymaker,Junya Fujimoto,Stephen G. Swisher,John V. Heymach,Don L. Gibbons,John Lee,Boris Sepesi,Tina Cascone,Luisa M. Solis,Mariano Provencio,Ignacio I. Wistuba,Humam Kadara

DOI: https://doi.org/10.1158/1078-0432.22486923

2023-01-01

Abstract:Supplementary Data from Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC
Supplemental Material-Figure S5 from Blocking NF-κB is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer

Xiaomao Guo,Zheng Li,Jianxin Jiang,Yan Zhao,Xin Wang,Ming Shen,Feng Zhu,Rui Tian,Changcheng Shi,Meng Xu,Xu Li,Pingfa Feng,Hang Zhang,Yechen Feng,Yuan Xie,Xiaodong Xu,Jia Wang,Ruizhi He,Chencheng Xie,Jun Hu,Dawei Ye,Min Wang,Renyi Qin

DOI: https://doi.org/10.1158/1078-0432.22459142.v1

2023-01-01

Abstract:Figure S5: IL-18 promotes PC cell proliferation, invasion and metastasis.
Supplementary Data from the Mechanism of Anti–PD-L1 Antibody Efficacy Against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 As a Cytolytic Effector

Wenjuan Dong,Xiaojin Wu,Shoubao Ma,Yufeng Wang,Ansel P. Nalin,Zheng Zhu,Jianying Zhang,Don M. Benson,Kai He,Michael A. Caligiuri,Jianhua Yu

DOI: https://doi.org/10.1158/2159-8290.22532669.v1

2023-01-01

Abstract:Supplementary figures and figure legends as well as supplementary methods and materials
FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer

Lu Lu,Yi-Xin Jiang,Xiao-Xia Liu,Jin-Mei Jin,Wen-Jie Gu,Xin Luan,Ying-Yun Guan,Li-Jun Zhang

DOI: https://doi.org/10.1080/2162402X.2023.2217024

2023-05-27

OncoImmunology

Abstract:Colorectal cancer (CRC) is one of the top three malignant tumors in terms of morbidity, and the limited efficacy of existing therapies urges the discovery of potential treatment strategies. Immunotherapy gradually becomes a promising cancer treatment method in recent decades; however, less than 10% of CRC patients could really benefit from immunotherapy. It is pressing to explore the potential combination therapy to improve the immunotherapy efficacy in CRC patients. It is reported that Farnesoid X receptor (FXR) is deficiency in CRC and associated with immunity. Herein, we found that GW4064, a FXR agonist, could induce apoptosis, block cell cycle, and mediate immunogenic cell death (ICD) of CRC cells in vitro. Disappointingly, GW4064 could not suppress the growth of CRC tumors in vivo. Further studies revealed that GW4064 upregulated PD-L1 expression in CRC cells via activating FXR and MAPK signaling pathways. Gratifyingly, the combination of PD-L1 antibody with GW4064 exhibited excellent anti-tumor effects in CT26 xenograft models and increased CD8 + T cells infiltration, with 33% tumor bearing mice cured. This paper illustrates the potential mechanisms of GW4064 to upregulate PD-L1 expression in CRC cells and provides important data to support the combination therapy of PD-L1 immune checkpoint blockade with FXR agonist for CRC patients.

oncology,immunology
Supplementary Figure S12 from CD24hiCD27+ Bregs Within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer

Huanhuan Huang,Yao,Lesang Shen,Jingxin Jiang,Ting Zhang,Jia Xiong,Jiaxin Li,Shanshan Sun,Siwei Zheng,Fang Jia,Jun Zhou,Xiuyan Yu,Wuzhen Chen,Jun Shen,Wenjie Xia,Xuan Shao,Qingqing Wang,Jian Huang,Chao Ni

DOI: https://doi.org/10.1158/1078-0432.24826170

2023-01-01

Abstract:Fig. S12. The addition of anti-PD1/PD-L1 to neoadjuvant chemotherapy improves the pCR rate of patients with mLNs.
Farnesoid X Receptor, a Novel Proto-Oncogene in Non-Small Cell Lung Cancer, Promotes Tumor Growth Via Directly Transactivating CCND1

Wenjie You,Bi Chen,Xueqing Liu,Shan Xue,Hui Qin,Handong Jiang

DOI: https://doi.org/10.1038/s41598-017-00698-4

IF: 4.6

2017-01-01

Scientific Reports

Abstract:Farnesoid X receptor (FXR), a nuclear receptor for maintaining bile acid homeostasis, has been recognized as a tumor suppressor in enterohepatic tissues. However, its expression and functional role in non-small cell lung cancer (NSCLC) remain unclear. We report that FXR is significantly increased in NSCLC and that it predicts poor clinical outcomes in NSCLC patients. FXR knockdown in NSCLC cells inhibited in vitro cell proliferation, blocked xenograft growth in nude mice, and delayed the G1/S transition of the cell cycle, whereas ectopic overexpression of FXR promoted NSCLC cell proliferation. Mechanistic analysis demonstrated that FXR could directly bind to an inverted repeat-0 sequence in the CCND1 promoter and activate its transcription. Cyclin D1 overexpression rescued NSCLC cells from the delayed G1/S transition and the impaired cell proliferation induced by FXR knockdown. Importantly, a positive correlation between the expression of FXR and cyclin D1 was confirmed in NSCLC samples, and patients with high expression of both FXR and cyclin D1 had the worst prognosis. In summary, our results suggest that FXR has oncogenic potential in NSCLC development, providing mechanistic insights that could be exploited for both prognostic and therapeutic purposes.
Supplementary Data from Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis

Rui Jin,Boxuan Liu,Xiuju Liu,Yijian Fan,Wei Peng,Chunzi Huang,Adam Marcus,Gabriel Sica,Melissa Gilbert-Ross,Yuan Liu,Wei Zhou

DOI: https://doi.org/10.1158/1535-7163.22520611

2023-01-01

Abstract:Supplemental Figures and Tables

Supplementary Data from Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti–PD-1 Immunotherapy

Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti–PD-1 Immunotherapy

Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[&lt;sup&gt;18&lt;/sup&gt;F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

High Farnesoid X Receptor Expression Predicts Favorable Clinical Outcomes in PD‑L1low/negative Non‑small Cell Lung Cancer Patients Receiving Anti‑pd‑1‑based Chemo‑immunotherapy.

Supplementary Data from Genomic Characteristics and Single-Cell Profiles after Immunotherapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma

Supplementary Data from XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti–PD-1 Efficacy

Supplementary Data from LRP6 Ectodomain Prevents SDF-1/CXCR4-Induced Breast Cancer Metastasis to Lung

Supplementary Table 4 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity

Supplementary Data from PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses Against Tumor

Supplementary Table 5 from Androgen Signaling Contributes to Sex Differences in Cancer by Inhibiting NF-κB Activation in T Cells and Suppressing Antitumor Immunity

Supplementary Data from Regorafenib Promotes Antitumor Immunity Via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Supplementary Figure from IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment

Supplementary Data from Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC

Supplemental Material-Figure S5 from Blocking NF-κB is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer

Supplementary Data from the Mechanism of Anti–PD-L1 Antibody Efficacy Against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 As a Cytolytic Effector

FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer

Supplementary Figure S12 from CD24hiCD27+ Bregs Within Metastatic Lymph Nodes Promote Multidrug Resistance in Breast Cancer

Farnesoid X Receptor, a Novel Proto-Oncogene in Non-Small Cell Lung Cancer, Promotes Tumor Growth Via Directly Transactivating CCND1

Supplementary Data from Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis

Supplementary Data from A Paradigm of Cancer Immunotherapy Based on 2-[<sup>18</sup>F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect